


## Envonalkib citrate

Cat. No.:	HY-145566A
CAS No.:	1867204-56-5
Molecular Formula:	C <sub>30</sub> H <sub>34</sub> Cl <sub>2</sub> FN <sub>5</sub> O <sub>9</sub>
Molecular Weight:	698.52
Target:	Anaplastic lymphoma kinase (ALK)
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Envonalkib citrate is a potent and orally active inhibitor of ALK, with IC <sub>50</sub> s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib citrate can be used for the research of non-small cell lung cancer <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC <sub>50</sub> : 1.96 nM (WT-ALK), 35.1 nM (mutated L1196M-ALK), 61.3 nM (mutated G1269S-ALK) <sup>[1]</sup>
In Vivo	Envonalkib citrate (formula I) (12.5-25 mg/kg; p.o. once daily for 14 days) inhibits the growth of human non-small cell lung cancer NCI-H2228 nude mice xenografts <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Feng G, et, al. Pyridine-substituted 2-aminopyridine protein kinase inhibitors. WO2016015676A1.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA